MOBILE试验:自体骨髓细胞治疗严重外周动脉疾病所致重症肢体缺血的原理与设计
MOBILE是一项多中心、随机、双盲、安慰剂对照试验,评估经MarrowStim采集的浓缩骨髓穿刺液(cBMA)肌内注射能否改善不适合外科血运重建的重症肢体缺血(CLI)患者的无截肢生存。纳入标准包括年龄>21岁、静息痛或组织缺损,且踝肱指数<0.6、趾肱指数<0.4或经皮氧分压<50 mm Hg。152例患者已完成治疗和1年随访,长期随访仍在进行,初步结果正在揭盲分析。
要点
- MOBILE试验针对不适合外科血运重建的“poor-option”CLI患者,评估cBMA肌内注射的疗效。
- 纳入标准包括ABI<0.6、TBI<0.4或TcPO2<50 mm Hg,且年龄>21岁。
- 152例患者已完成治疗和1年随访,长期随访进行中,初步结果正在揭盲。
核心结论
- 若MOBILE试验成功,将为cBMA治疗poor-option CLI患者提供确定性高质量证据,并为面临截肢的患者提供额外治疗方式。
研究设计与样本
- MOBILE是一项多中心、随机、双盲、安慰剂对照试验,旨在评估cBMA肌内注射促进无截肢生存的疗效。
- 研究纳入年龄>21岁、因晚期外周动脉疾病导致静息痛或组织缺损且不适合外科血运重建的患者。
主要发现
- 152例入组患者已完成治疗和1年随访,长期随访仍在进行中。
- 目前正在揭盲初始结果以进行初步数据分析。
关键数值与推荐
- 纳入标准:年龄>21岁,静息痛或组织缺损,ABI<0.6、TBI<0.4或TcPO2<50 mm Hg,且因晚期病变无法进行外科血运重建。
临床怎么用
- 若试验成功,cBMA或可作为不适合外科血运重建的CLI患者的附加治疗选择。
局限性
- 初步结果尚未揭盲,疗效结论尚未获得。
- 长期随访仍在进行中,长期结局数据未报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Critical limb ischemia (CLI) continues to place a significant encumbrance on patients and the health care system as it progresses to limb loss and long-term disability. Traditional methods of revascularization offer a significant benefit; however, for one-third of CLI patients, these surgical options are not technically possible or patency is severely limited by disease burden (deemed "poor-option" for revascularization). In a previous phase I trial, we demonstrated intramuscular injection of concentrated bone marrow aspirate (cBMA) via MarrowStim (Zimmer Biomet, Warsaw, Ind) harvest is safe and may decrease major amputation in patients with CLI unfit for surgical revascularization. Therefore, we describe and rationalize the MarrowStim PAD Kit for the Treatment of Critical Limb Ischemia in Subjects with Severe Peripheral Arterial Disease (MOBILE) trial, a study geared to provide the pivotal proof of efficacy of cBMA in CLI. METHODS: MOBILE is a multicenter, randomized, double-blind, placebo-controlled trial designed to assess the efficacy of intramuscular injections of cBMA in promoting amputation-free survival in patients with poor-option CLI. Patients (aged >21 years) with rest pain or tissue loss resulting from advanced peripheral arterial disease, as characterized by ankle-brachial index (<0.6), toe-brachial index (<0.4), or transcutaneous pressure of oxygen (<50 mm Hg), were eligible for inclusion if surgical revascularization was not possible secondary to advanced disease. RESULTS: Treatment and 1-year follow-up of 152 patients enrolled in MOBILE are completed. Long-term follow-up is ongoing. Currently, we are in the process of unblinding the initial results for preliminary data analysis. CONCLUSIONS: If successful, MOBILE could add definitive, high-quality evidence in support of cBMA for the treatment of poor-option CLI patients and provide an additional modality for patients who face amputation secondary to advanced limb ischemia.
引用
- Wang SK, Green LA, Motaganahalli RL, et al. Rationale and design of the MarrowStim PAD Kit for the Treatment of Critical Limb Ischemia in Subjects with Severe Peripheral Arterial Disease (MOBILE) trial investigating autologous bone marrow cell therapy for critical limb ischemia. J Vasc Surg. 2017. PMID: 28390770. doi:10.1016/j.jvs.2017.01.054
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。